Pharmaceutical and biotech companies listed in the first half marked a slower rise in stock price gains than non-pharmaceutical counterparts, data showed Tuesday.The eight pharma and biotech companies that went public in the first half of this year are Korea Arlico Pharm, DongKoo Bio & Pharma, EDGC (Eone Diagnomics Genome Center), Enzychem Lifesciences, Osteonic, Carelabs, Genoray, and Sejong
The Moon Jae-in administration has vowed to boost support for state dementia examinations and long-term nursing services, but such efforts could end up being wasted due to lack of dementia treatments, an expert said.Among available dementia treatments, acetylcholinesterase inhibitors (ACEI) are said to be more effective to preserve cognitive functions than conventional remedies.Marketed AC
Eliquis (ingredient: apixaban) by Bristol-Myers Squibb Korea and Korea Pfizer had the lowest bleeding risk among non-vitamin K antagonist oral anticoagulants (NOAC) for Korean patients with artrial fibrillation (AF), government data showed.0The National Evidence-based Healthcare Collaborating Agency (NECA) on Monday released real-world data analysis on NOACs in comparison to warfarin in 56,000
Bristol-Myers Squibb (BMS) Korea said it has won a suit against domestic drugmakers over the composition-of-matter patent of Eliquis (ingredient: apixaban), a cardiovascular drug.According to the company, the Seoul Central District Court on Wednesday recognized the validity of the Eliquis patent in the suit against local drug firms. Upon the decision, the court banned all kinds of patent infri
A new biomarker in urine to predict childhood obesity complications might be tested in a clinical trial.According to the Korean Intellectual Property Office, the Seoul National University Hospital and Inje University Industry-Academic Cooperation Foundation have obtained a patent for “Prognostic marker for diagnosis of obesity of complications associated with obesity” on Friday. It is a techni
The Korean government has developed a technology to freeze human blood using Antarctic sea microorganisms and conserve it for more than six months, sources said Tuesday. The government is soon to transfer the technology to a private biotech firm, they said.The Korea Polar Research Institute of Marine Research Placement (KOPRI), run under the Ministry of Oceans and Fisheries, developed the tech
Korea’s pharmaceutical exports to the U.S. and Europe have expanded over the past five years, a report showed.According to the Korea Health Industry Development Institute (KHIDI)’s report released on Monday, Korea’s drug exports grew more than 17 percent per year on average, or 1.9 folds, between 2013 and 2017.Last year, in particular, the nation had the best performance in drug exports, w
Chong Kung Dang, a local pharmaceutical firm, beat multinational rivals by winning approval for clinical trials the most in the first half. Clinical research is one of the measures to gauge a drug firm’s capability to develop new medicines.According to the Ministry of Food and Drug Safety, Chong Kun Dang obtained approval for 11 clinical trials, the most among all pharmaceutical companies oper
More than 60 percent of biotech companies listed on KOSDAQ suffered operating profit declines in the first quarter from a year earlier, industry data showed Tuesday.According to disclosed earnings at 48 companies, 22 of them had an operating loss, and the rest 26 had operating profits in the first quarter. Among them, 30 firms had their operating incomes worsening or turning to losses in the f
Neuronox, the botulinum toxin developed by Medytox that is seeking China’s regulatory approval, will be worth about 600 billion won ($542.8 million) in the Chinese market, an analyst said Monday.Neuronox is the brand name of Medytoxin in China. Medytox finished phase 3 clinical trials for Neuronox in China in June 2017.Kim Tae-hee, an analyst at Mirae Asset Daewoo, estimated Neuronox’ valu
The pharmaceutical industry is actively discussing merits of sodium-glucose transport protein 2 (SGLT-2) inhibitors and precautions in prescribing them. SGLT-2 inhibitors are antidiabetic treatments to lower blood sugar and cardiovascular disease risks.Cardiovascular disease is the most common cause of death in type-2 diabetes patients, accounting for half of all deaths of type-2 diabetes pati
Immunotherapies and gastrointestinal cancer drew the most attention during the annual meeting of the American Society of Clinical Oncology (ASCO), which closed on June 5, an analyst said Thursday.According to a report by Lee Tae-young, an analyst at Meritz Securities, participants of the conference announced their clinical data on tumors in the gastrointestinal system (excluding colon and rect
Dongkook Pharmaceutical, Chong Kung Dang Healthcare, and Sanofi-Aventis Korea ranked high in the local functional foods market excluding pharmacies in the first quarter, industry data showed.According to Nielsen Korea’s data on the distribution channels except for pharmacies, Dongkook’s products under the brand name Nature’s Vitamin Shop sold the most in the first quarter. Next came Chong Kun
Korean and global pharmaceutical companies disclosed their newest clinical data on anticancer pipelines at the American Society of Clinical Oncology conference, which ran from Friday to Tuesday in Chicago, the U.S.Ono Pharma Korea and Bristol-Myers Squibb Korea Pharmaceutical on Monday announced partial results of their phase-3 study CheckMate-227 on Opdivo (ingredient: nivolumab), an anticanc
Gilead Sciences Korea seems to have successfully switched its key drug in HIV therapy to Genvoya from Stribild.Genvoya, a combination drug, had the largest market share in the “backbone” HIV treatment market in the first quarter. Backbone drug refers to a key component in combination therapies.Genvoya combines three agents – tenofovir alafenamide (TAF), elvitegravir, and emtricitabine.
Guerbet Korea has recently come under fire for threatening to stop the supply of its contrast medium Lipiodol unless the government raises the drug price by five folds.Lipiodol is the only agent used in combination with anticancer drugs in transarterial chemoembolization (TACE) procedures for liver cancer patients.Critics say the French pharmaceutical firm is abusing its monopolistic power
Baxter’s Theranova, a blood filter for artificial kidneys, can be more effective in removing uremic substances than conventional hemodialysis devices, an expert said. Baxter released the product last year.Chang Jai-won, a professor at nephrology department of Asan Medical Center, expressed his opinion about Theranova when he spoke on “how Theranova affects dialysis patients’ nutrition improvem
The health authorities said they would start analyzing the cost-effectiveness of pneumococcal conjugate vaccines (PCV) for children, made by Pfizer and GlaxoSmithKline. GSK’s Synflorix, a PCV10 treatment for children, and Pfizer’s PCV13 product, marketed as Prevnar13, have been included in the National Immunization Program (NIP) since May 2014.The Korea Centers for Disease Control and Prev
Korea exported pharmaceutical products to Europe the most and medical devices to China the most in the first four months of this year, government data showed. According to the Korea Trade-Investment Promotion Agency (KOTRA)’s report, Korea exported $376 million worth of drugs to European Union between January and April. The volume was an 81.3 percent increase from the same period last year
A recent court decision took a massive blow to Reyon Pharmaceutical, which has been fighting a patent legal battle against ViroMed over VM202, gene therapy to treat diabetic neuropathy.The Seoul Central District Court dismissed Reyon’s petition against ViroMed for a transfer of the holder of VM202’s patent rights on Thursday last week.In November, Reyon filed the lawsuit to claim that it s